FRIDAY, SEPTEMBER 30, 2016

AIDS vaccine candidate successfully stimulates immune system

AIDS vaccine candidate stimulates immune system | Courtesy of medicalexpo.com

A team of researchers from The Scripps Research Institute (TSRI), the Rockefeller University and International AIDS Vaccine Initiative recently conducted a study that shows an experimental AIDS vaccine candidate can successfully stimulate the immune system to halt HIV infections.

The research, which was conducted on mice, increases immune system activity enough that it stops an HIV infection from developing. The results of this study may be crucial to creating an efficient vaccine for AIDS and show that there is progress in creating a vaccine for HIV, which has proven challenging.

HIV has shown a remarkable ability to avoid being detected by the immune system, while the virus mutates into new strains at a fast pace. This makes it difficult to create a vaccine for the infection. So far, none of the HIV vaccines successfully provoke antibodies or immune system molecules into defending the body against the virus.

The study’s co-leaders included Dennis Burton, chair of the TSRI Department of Immunology and Microbial Science and scientific director of two centers at TSRI, the IAVI Neutralizing Antibody Consortium (NAC) and the National Institutes of Health (NIH) Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID); David Nemazee, TSRI professor; William Schief, IAVI NAC associate director of vaccine design; and Michel Nussenzweig, a Zanvil A. Cohn and Ralph M. Steinman Professor at the Rockefeller University and a Howard Hughes Medical Institute Investigator.

Further details are available in the June 18, 2015 issue of Cell and Science.

Organizations in this story

Scripps Research Institute 10550 North Torrey Pines Road La Jolla, CA

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about any of these organizations!